Because immunotherapies like aducanumab and lecanemab change disease biology, “there are a number of different studies — phase 2 and 3 studies — that show it makes a difference in cognition and function,” Foster said.

Source: https://www.deseret.com/2023/1/23/23546444/medicare-doctors-among-barriers-to-alzheimers-disease-treatment

Biogen is developing lecanemab in partnership with Eisai, with all research, sales, and marketing costs to be shared equally between the two companies.

Source: https://seekingalpha.com/article/4575506-biogen-stock-what-to-do-ahead-of-q4-earnings?source=feed_all_articles

But their deaths occurred after that phase of the trial, when they were knowingly being treated with lecanemab in what’s known as an open-label extension study.

Source: https://www.nytimes.com/2023/01/06/health/alzheimers-drug-leqembi-lecanemab.html

Even lecanemab, the new amyloid-targeting Alzheimer’s medication that towards the end of 2022, only offers marginal benefits in slowing down memory loss.

Source: https://www.theguardian.com/society/2023/feb/19/could-alzheimers-be-caused-by-an-infection

For example, the most recent anti-Alzheimer’s drug to win FDA approval is lecanemab.

Source: https://www.forbes.com/sites/howardgleckman/2023/05/17/the-war-over-whether-medicare-should-pay-for-the-new-anti-alzheimers-drugs/

This application is based on the results of the Phase 3 Clarity AD study and the Phase clinical study, which demonstrated that lecanemab treatment showed a reduction of clinical decline in early AD.

Source: https://www.prnewswire.com/news-releases/bioarctics-partner-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-the-eu-301718616.html